A Randomized, Double-Blind, Active-Controlled, 4-week Parallel GroupStudy to Evaluate the Efficacy and Safety of Lactitol and Probiotic Bacillus Coagulans SC208 in patients with Chronic Idiopathic Constipation. - Lactiliq-TM Syrup

开始日期2022-10-31

申办/合作机构

Synergia Life Sciences Pvt Ltd.

[+1]

CTRI/2022/06/043558 / CompletedN/A

A randomized, double blind, placebo controlled clinical trial to evaluate the efficacy and safety of MXP22 on liver health

开始日期2022-07-01

申办/合作机构

Synergia Life Sciences Pvt Ltd.

CTRI/2022/03/041503 / CompletedN/A

An Open Label, Single Arm, Study to Assess the Efficacy and Safety of Menaquinone-7 (Vitamin K2-7) in Subjects with Diabetic Peripheral Neuropathy

开始日期2022-04-05

申办/合作机构

Synergia Life Sciences Pvt Ltd.

100 项与 Synergia Life Sciences Pvt Ltd. 相关的临床结果

登录后查看更多信息

0 项与 Synergia Life Sciences Pvt Ltd. 相关的专利（医药）

登录后查看更多信息

项与 Synergia Life Sciences Pvt Ltd. 相关的文献（医药）

2023-11-20·Diabetic Nephropathy

Current clinical insights into circRNAs and signal transduction in diabetic nephropathy

作者: Mehta, Dilip ; Ajgaonkar, Saiprasad ; Nair, Sujit ; Basudkar, Vivek

AbstractDiabetic nephropathy (DN) is a chronic kidney disease that occurs in patients with diabetic mellitus. In the United States of America, one in three people with diabetes suffers from DN. Globally, DN occurs in 30%–40% of patients diagnosed with diabetes. Circular ribonucleic acids (circRNAs) are non-coding, closed-loop RNAs that play critical roles in regulating gene expression by sponging microRNAs (miRNAs). Recent studies have implicated circRNAs in the regulation of various diseases including DN. We delineate circRNA biological networks from the evidence gleaned from clinical studies. Further, we elucidate circRNA-associated signal transduction pathways in the pathogenesis of DN. Taken together, this will facilitate the discovery of novel circRNA and/or miRNA biomarkers for diagnostic and/or therapeutic intervention in DN.

Frontiers in Pharmacology2区 · 医学

New Vistas in microRNA Regulatory Interactome in Neuropathic Pain

2区 · 医学

ReviewOA

作者: Nair, Sujit ; Mehta, Dilip ; Gada, Yash ; Pandey, Amitkumar ; Jadhav, Nikita ; Ajgaonkar, Saiprasad

Neuropathic pain is a chronic pain condition seen in patients with diabetic neuropathy, cancer chemotherapy-induced neuropathy, idiopathic neuropathy as well as other diseases affecting the nervous system. Only a small percentage of people with neuropathic pain benefit from current medications. The complexity of the disease, poor identification/lack of diagnostic and prognostic markers limit current strategies for the management of neuropathic pain. Multiple genes and pathways involved in human diseases can be regulated by microRNA (miRNA) which are small non-coding RNA. Several miRNAs are found to be dysregulated in neuropathic pain. These miRNAs regulate expression of various genes associated with neuroinflammation and pain, thus, regulating neuropathic pain. Some of these key players include adenylate cyclase (Ac9), toll-like receptor 8 (Tlr8), suppressor of cytokine signaling 3 (Socs3), signal transducer and activator of transcription 3 (Stat3) and RAS p21 protein activator 1 (Rasa1). With advancements in high-throughput technology and better computational power available for research in present-day pharmacology, biomarker discovery has entered a very exciting phase. We dissect the architecture of miRNA biological networks encompassing both human and rodent microRNAs involved in the development of neuropathic pain. We delineate various microRNAs, and their targets, that may likely serve as potential biomarkers for diagnosis, prognosis, and therapeutic intervention in neuropathic pain. miRNAs mediate their effects in neuropathic pain by signal transduction through IRAK/TRAF6, TLR4/NF-κB, TXIP/NLRP3 inflammasome, MAP Kinase, TGFβ and TLR5 signaling pathways. Taken together, the elucidation of the landscape of signature miRNA regulatory networks in neuropathic pain will facilitate the discovery of novel miRNA/target biomarkers for more effective management of neuropathic pain.

Pharmaceuticals

Current Insights into miRNA and lncRNA Dysregulation in Diabetes: Signal Transduction, Clinical Trials and Biomarker Discovery

Review

作者: Pandey, Amitkumar ; Ajgaonkar, Saiprasad ; Nair, Sujit ; Panda, Sangita ; Mehta, Dilip ; Gurav, Pranay ; Jadhav, Nikita ; Saha, Praful

Diabetes is one of the most frequently occurring metabolic disorders, affecting almost one tenth of the global population. Despite advances in antihyperglycemic therapeutics, the management of diabetes is limited due to its complexity and associated comorbidities, including diabetic neuropathy, diabetic nephropathy and diabetic retinopathy. Noncoding RNAs (ncRNAs), including microRNAs (miRNAs) and long noncoding RNAs (lncRNAs), are involved in the regulation of gene expression as well as various disease pathways in humans. Several ncRNAs are dysregulated in diabetes and are responsible for modulating the expression of various genes that contribute to the ‘symptom complex’ in diabetes. We review various miRNAs and lncRNAs implicated in diabetes and delineate ncRNA biological networks as well as key ncRNA targets in diabetes. Further, we discuss the spatial regulation of ncRNAs and their role(s) as prognostic markers in diabetes. We also shed light on the molecular mechanisms of signal transduction with diabetes-associated ncRNAs and ncRNA-mediated epigenetic events. Lastly, we summarize clinical trials on diabetes-associated ncRNAs and discuss the functional relevance of the dysregulated ncRNA interactome in diabetes. This knowledge will facilitate the identification of putative biomarkers for the therapeutic management of diabetes and its comorbidities. Taken together, the elucidation of the architecture of signature ncRNA regulatory networks in diabetes may enable the identification of novel biomarkers in the discovery pipeline for diabetes, which may lead to better management of this metabolic disorder.

100 项与 Synergia Life Sciences Pvt Ltd. 相关的药物交易

登录后查看更多信息

100 项与 Synergia Life Sciences Pvt Ltd. 相关的转化医学

登录后查看更多信息